BARRECA, MARCO
BARRECA, MARCO
DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE
Development and validation of a gene expression-based Breast Cancer Purity Score
2024 Barreca, M; Dugo, M; Galbardi, B; Győrffy, B; Frassoldati, A; Zambetti, M; Mansutti, M; Zamagni, C; Del Mastro, L; Colleoni, M; Bisagni, G; Gianni, L; Antón-Torres, A; García Sáenz, J; Ciruelos Gil, E; Sevillano, E; Falo, C; Bermejo, B; Volkov, N; Gennadievich, A; Frolova, M; Semiglazov, V; Malter, W; Schumacher, C; Schneeweiss, A; Lück, H; Tesch, H; Behringer, D; Graffunder, G; Sagasser, J; Thill, M; Egle, D; Greil, R; O'Connor, M; Kennedy, J; Morris, P; O'Reilly, S; Kelly, C; Tseng, L; Liu, L; Hou, M; Chen, S; Huang, C; Russo, S; Bianchini, G; Zambelli, S; Gambaro, A; Mariani, G; Bengala, C; Montemurro, F; Valagussa, P; Besozzi, D; Viale, G; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
2023 Licata, L; Barreca, M; Galbardi, B; Dugo, M; Viale, G; Gyorffy, B; Karn, T; Pusztai, L; Gianni, L; Callari, M; Bianchini, G
Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment
2022 Callari, M; Barreca, M; Dugo, M; Galbardi, B; Vigano, L; Locatelli, A; Licata, L; Viale, G; Valagussa, P; Viale, G; Gianni, L; Bianchini, G
Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial
2022 Callari, M; Huang, C; Egle, D; Bermejo, B; Zamagni, C; Dugo, M; Thill, M; Anton, A; Barreca, M; Russo, S; Ciruelos, E; Greil, R; Zambelli, S; Gyorffy, B; Smart, C; Biasi, O; Valagussa, P; Viale, G; Gianni, L; Bianchini, G